Earnings digests and industry comparisons for Japan's biggest listed companies.
640 reports(page 7 of 54)
Japan's two major airlines both grew revenue but posted lower profit in Q1 FY2027. ANA's sales rose 22.6% to ¥672.7 billion, while JAL's operating profit dropped 72.1%, versus a 43.5% decline at ANA, as fuel costs rose.
Revenue growth failed to offset higher fuel costs, widening the profit gap.
Japan's Big Three JR Operators posted mixed Q1 FY2027 results: JR East lifted revenue 8.0% to a record, while JR Central held a 44.5% operating margin. JR West's sales and profit fell as costs rose.
JR East is growing fastest, while JR Central leads on profitability.
Japan's Big 3 telecom carriers all grew revenue and profit in Q1 FY2026, with NTT leading sales growth at 10.9%. KDDI's operating profit jumped 21.1%, highlighting the gap between NTT's scale and KDDI's earnings momentum.
NTT leads in scale, while KDDI leads in profit growth.
Japan's Big 3 Electric Utilities all grew revenue in Q1 FY2027, but operating results diverged sharply. Kansai Electric remained profitable while Chubu Electric and TEPCO posted losses; Kansai's net profit also included a one-off share sale gain.
Revenue rose, but core profitability diverged sharply.
Japan's Big Five Real Estate Developers all grew revenue and operating profit in FY2026; only Tokyo Tatemono's net profit fell. Tokyu Fudosan HD led net-profit growth at 24.7%, while Sumitomo Realty topped margins at 28.3%; Tokyo Tatemono has a different fiscal year-end.
Scale, growth and efficiency produced different leaders.
Japan's Big Pharma posted average sales growth of 7.7% in FY2026, with eight of nine companies expanding. Margins ranged from Chugai's 47.6% to Eisai's 5.3%, as earnings reflected both drug growth and one-off gains.
Sales growth and earnings quality separated the winners from the laggards.
Specialty and Functional Chemicals companies delivered mixed results for FY2026, as semiconductor materials lifted some earnings while basic chemicals struggled. Nissan Chemical led on growth, while Shin-Etsu kept the top operating profit and Kuraray's net income plunged on impairment losses.
Higher-value products widened the earnings gap.
Japan's six major chemical groups all lifted sales and operating profit in Q1 FY2027, but gains had different drivers. Mitsubishi Chemical led in scale and margin, Mitsui Chemicals in growth, while UBE's net profit fell.
Every company grew, but the sources of profit growth diverged.
Japan's Big 3 Securities Firms all grew revenue and profit in Q1 FY2027 as markets rallied. Daiwa led revenue growth at 33.1%, while SBI's 149.9% profit gain topped the group, reflecting different earnings drivers.
All grew revenue, but profit growth came from different sources.
Regional and mid-tier banks all posted higher revenue and profit in Q1 FY2027 as rising rates lifted funding income. FFG led revenue at ¥151.9 billion, while Shizuoka FG topped profit at ¥47 billion; Aozora led net-income growth.
Higher rates helped all five, but gains varied sharply.
Japan's Big 3 Megabanks all grew revenue and profit in Q1 FY2027 as higher rates lifted lending income. MUFG led net profit growth at 48.2%, while Mizuho posted the fastest ordinary profit growth.
All three banks grew, but profit growth rates diverged.
